OREANDA-NEWS. The anti-flu drug Favipiravir (also known as Avigan) has shown its clinical efficacy in the treatment of diseases caused by a new type of coronavirus. This was announced at a press conference by the head of the Center of Biotechnology under the Science and Technology Ministry of the People’s Republic of China, Zhang Xinmin.

Favipiravir has already passed through clinical trials that have demonstrated good clinical efficacy in treating COVID-19, he said. According to the scientist, “patients who took Favipiravir recovered faster, and their lungs improved much faster.” “In terms of security, Favipiravir was approved for sale in Japan in 2014, and there have been no concurrent reactions since it entered the market,” the chief of the Center of Biotechnology added.